Immunotherapy in advanced renal cell carcinoma

For patients with treatment-naïve advanced renal cell carcinoma, pembrolizumab plus axitinib offers superior overall survival to sunitinib, confirms an updated analysis from the KEYNOTE-426 trial.

With expert video commentary from Elizabeth Plimack

Research suggests that patients with metastatic clear cell renal cell carcinoma with disease progression after immune checkpoint inhibitor therapy may benefit from the combination of lenvatinib and pembrolizumab.

With expert video commentary from Chung-Han Lee

Initial results from the trial suggest that some patients with advanced RCC may benefit from nivolumab plus ipilimumab after immune checkpoint inhibitor therapy.

With expert video commentary from Toni Choueiri

The final 5-year analysis of the CheckMate 025 trial comprising patients with advanced RCC confirms the enhanced survival benefits of nivolumab versus everolimus.

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic RCC regardless of histology.

Results from two studies presented at ASCO 2020 suggest that using single-agent nivolumab followed by ipilimumab cannot be recommended for patients with advanced RCC.

Yann-Alexander Vano discusses the results of a translational analysis of the NIVOREN GETUG-AFU 26 trial (3:29).

Ziad Bakouny outlines his research investigating response to immune checkpoint inhibitors in sarcomatoid and rhabdoid renal cell carcinoma (4:14).

Results from the ADAPTeR study show the promise of nivolumab before and after cytoreductive nephrectomy or metastatic biopsy for treatment-naïve metastatic clear cell RCC. 

With expert video commentary from Guillermo de Velasco (6:07).

A quick-reference guide to the IMmotion trials evaluating the anti-PD-L1 agent atezolizumab for the treatment of renal cell carcinoma.

A quick-access guide to the JAVELIN trials of the anti-PD-L1 agent avelumab in the renal cell carcinoma setting.

A quick-reference guide to the KEYNOTE clinical trials evaluating the immune checkpoint inhibitor pembrolizumab in patients with renal cell carcinoma.